Biotechnology company GenScript Biotech BV announced on Wednesday that it has entered into an agreement for the exclusive distribution of its GenScript cPass SARS-CoV-2 Neutralization Antibody Detection Kit in Spain, Portugal through Andorra IES Diagnostics, a life science company.
The GenScript cPass SARS-CoV-2 Neutralization Antibody Detection test reportedly measures the presence of neutralizing antibodies (NAbs) in patients recovering from COVID-19 or receiving a vaccine.
In addition, the GenScript cPass SARS-CoV-2 Neutralization Antibody Detection test is the only US FDA Emergency Use Authorized (EUA) serology test for neutralizing antibodies from recent and prior SARS-CoV-2 infections.
According to the company, the kit is CE marked (Europe), with HSA provisional approval in Singapore, ANVISA in Brazil, ANMAT in Argentina and clearance from the Ministry of Health and Prevention (MOHAP) in the United Arab Emirates as a medical device.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine